Thomas Boyd
Hematology & Oncology · Spokane, WANPI 1518049642
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by AbbVie at 46.0% of the total. Reporting peaked in 2019 at $67,974 and has fallen 99.9% since, to $99 in 2025. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $703.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$86K
- E.r. Squibb & Sons, L.L.C.$59K
- Bristol Myers Squibb$24K
- Roche Molecular Systems, Inc.$14K
- AstraZeneca$3K
- Incyte Corporation$151
- plus $981 from 23 others
Across 7 payments — averaging $2108.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$12K
- Acerta Pharma LLC$2K
- Genentech, Inc.$585
- E.r. Squibb & Sons, L.L.C.$375
What the payments were for
- Consulting fees$48,13726%
- Speaking & faculty fees$102,80955%
- Travel & lodging$30,03216%
- Food & beverage$5,9443%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 140 | $86,026 |
| E.r. Squibb & Sons, L.L.C. | 54 | $58,815 |
| Bristol Myers Squibb | 28 | $23,643 |
| Roche Molecular Systems, Inc. | 9 | $14,300 |
| AstraZeneca | 4 | $3,104 |
| Incyte Corporation | 2 | $151 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $132 |
| Genentech USA, Inc. | 2 | $122 |
| Beigene USA, Inc. | 1 | $109 |
| Johnson & Johnson | 2 | $96 |
| Seagen Inc. | 1 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $68 |
| Amgen | 2 | $31 |
| Tempus AI, Inc | 1 | $30 |
| Merck | 2 | $29 |
| CTI Biopharma Corp. | 1 | $25 |
| Roche Diagnostics Corporation | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Gilead | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $21 |
| Sobi, Inc | 1 | $21 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Epizyme, Inc. | 1 | $20 |
| Tesaro, Inc. | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| GSK | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Pharmaessentia USA Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$187,021 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Spokane
- William DittmanSpokane$150K
- Arvind ChaudhrySpokane$71K
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.